Skip to main content

A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers.

Publication ,  Journal Article
Maylott, SE; Lester, BM; Brown, L; Castano, AJ; Dansereau, L; Crowell, SE; Deboeck, P; Salisbury, A; Conradt, E
Published in: PLoS One
2024

Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. The goals of this protocol are to use these indicators shortly after birth to differentiate newborns who will be diagnosed with NOWS from those who will have mild/no withdrawal, to determine if the indicators predict development at 6 and 18 months of age, and to increase NOWS diagnostic sensitivity for earlier, more accurate diagnoses.

Duke Scholars

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2024

Volume

19

Issue

9

Start / End Page

e0306176

Location

United States

Related Subject Headings

  • Pregnancy
  • Opioid-Related Disorders
  • Neonatal Abstinence Syndrome
  • Male
  • Infant, Newborn
  • Infant
  • Humans
  • General Science & Technology
  • Female
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Maylott, S. E., Lester, B. M., Brown, L., Castano, A. J., Dansereau, L., Crowell, S. E., … Conradt, E. (2024). A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers. PLoS One, 19(9), e0306176. https://doi.org/10.1371/journal.pone.0306176
Maylott, Sarah E., Barry M. Lester, Lydia Brown, Ayla J. Castano, Lynne Dansereau, Sheila E. Crowell, Pascal Deboeck, Amy Salisbury, and Elisabeth Conradt. “A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers.PLoS One 19, no. 9 (2024): e0306176. https://doi.org/10.1371/journal.pone.0306176.
Maylott SE, Lester BM, Brown L, Castano AJ, Dansereau L, Crowell SE, et al. A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers. PLoS One. 2024;19(9):e0306176.
Maylott, Sarah E., et al. “A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers.PLoS One, vol. 19, no. 9, 2024, p. e0306176. Pubmed, doi:10.1371/journal.pone.0306176.
Maylott SE, Lester BM, Brown L, Castano AJ, Dansereau L, Crowell SE, Deboeck P, Salisbury A, Conradt E. A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers. PLoS One. 2024;19(9):e0306176.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2024

Volume

19

Issue

9

Start / End Page

e0306176

Location

United States

Related Subject Headings

  • Pregnancy
  • Opioid-Related Disorders
  • Neonatal Abstinence Syndrome
  • Male
  • Infant, Newborn
  • Infant
  • Humans
  • General Science & Technology
  • Female
  • Biomarkers